Janux Therapeutics
Update in progressJANX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies using its TRACTr, TRACIr and Adaptive Immune Response Modulator platforms to treat cancer and Autoimmune diseases. Lead assets include JANX007 (PSMA-TRACTr) in Phase 1 for metastatic castration-resistant prostate cancer and tumor vasculature; JANX008 (EGFR-TRACTr) in Phase 1 for several solid tumors; JANX011 (CD19 ARM) in Phase 1 for autoimmune disease. Partners include Merck and Bristol Myers Squibb. Founded 2017, based in San Diego.
Company score
- Sentiment
- 0.12
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.15
- Governance
- 0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.09
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. David Alan Campbell Ph.D.
- Founded2017
- Employees113
- Websitewww.januxrx.com
Identifiers
- ISINUS47103J1051
- FIGIBBG00ZHSKH11
- CUSIP47103J105
- CIK0001817713